| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_86c227a1644c83553c5f9b1fba0fa63d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7498a755446e3a1e93a1f100dd7302e8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a77b8cc427db284b23b54636b37e89a0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f6e39fb647151c551654257ee972cf09 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-434
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-608
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-61
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-416
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-436 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-022
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-82 |
| filingDate |
2010-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e60b478dbfa9e96d6cb4aa50c16a04d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_075cc37d758d6787a21589653812b49a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_37182ca216e3b17150f43a15b8779599
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e2e49491f966981027911c4ace6d7f8 |
| publicationDate |
2012-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2012130481-A1 |
| titleOfInvention |
Local vascular delivery of adenosine a2a receptor agonists in combination with other agents to reduce myocardial injury |
| abstract |
A stent or other implantable medical device for the local delivery of a selective adenosine receptor agonist may be utilized in combination with other therapeutic agents to reduce myocardial injury following an acute myocardial infarction. As soon as possible following an acute myocardial infarction a stent or other suitable device comprising and capable of delivering a selective adenosine receptor agonist is positioned in the blood vessel with the occlusion responsible for causing the infarct. Once in position , the stent or other intraluminal device is deployed to remove the occlusion and reestablish blood flow to the specific area, region or tissue volume of the heart. Over a given period of time the selective adenosine receptor agonist alone or in combination with other therapeutic agents elute from the stent or other device into the downstream coronary blood flow into the hypoxic cardiac tissue for a time sufficient to reduce the level of myocardial injury. |
| priorityDate |
2010-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |